Blake Marie Hauser, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Spinal Injuries | 2 | 2021 | 300 | 1.210 |
Why?
|
Night Blindness | 1 | 2024 | 56 | 0.930 |
Why?
|
Codon, Nonsense | 1 | 2024 | 285 | 0.850 |
Why?
|
Antibodies, Viral | 15 | 2024 | 3155 | 0.820 |
Why?
|
Electroretinography | 1 | 2024 | 521 | 0.820 |
Why?
|
Endophthalmitis | 1 | 2024 | 260 | 0.770 |
Why?
|
Eye Infections, Bacterial | 1 | 2024 | 242 | 0.760 |
Why?
|
Cataract Extraction | 1 | 2024 | 466 | 0.690 |
Why?
|
Craniotomy | 2 | 2023 | 741 | 0.670 |
Why?
|
Homozygote | 1 | 2024 | 1794 | 0.670 |
Why?
|
Antibodies, Neutralizing | 12 | 2024 | 1942 | 0.660 |
Why?
|
Viral Envelope Proteins | 1 | 2022 | 640 | 0.610 |
Why?
|
Patient Dropouts | 1 | 2017 | 412 | 0.490 |
Why?
|
Spinal Fractures | 1 | 2021 | 705 | 0.480 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2020 | 1351 | 0.460 |
Why?
|
Spinal Cord Injuries | 1 | 2021 | 924 | 0.440 |
Why?
|
Antibody Formation | 3 | 2024 | 1397 | 0.430 |
Why?
|
Students, Medical | 2 | 2024 | 1930 | 0.390 |
Why?
|
Meningioma | 1 | 2020 | 1218 | 0.380 |
Why?
|
Viral Tropism | 3 | 2016 | 102 | 0.380 |
Why?
|
Immunity, Humoral | 5 | 2022 | 604 | 0.370 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1069 | 0.350 |
Why?
|
Glasgow Coma Scale | 2 | 2021 | 580 | 0.330 |
Why?
|
Education, Medical | 1 | 2021 | 1726 | 0.330 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2020 | 2151 | 0.330 |
Why?
|
Epitopes | 4 | 2022 | 2504 | 0.320 |
Why?
|
Insurance Coverage | 1 | 2020 | 1934 | 0.320 |
Why?
|
Program Evaluation | 1 | 2017 | 2493 | 0.320 |
Why?
|
Germinal Center | 2 | 2022 | 380 | 0.310 |
Why?
|
Peptidyl-Dipeptidase A | 2 | 2020 | 361 | 0.310 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1863 | 0.310 |
Why?
|
Insurance, Health | 1 | 2020 | 2491 | 0.300 |
Why?
|
Hospitals | 2 | 2020 | 3873 | 0.290 |
Why?
|
Coronavirus Infections | 7 | 2020 | 3080 | 0.280 |
Why?
|
Pneumonia, Viral | 7 | 2020 | 3200 | 0.280 |
Why?
|
Patient Compliance | 1 | 2017 | 2689 | 0.280 |
Why?
|
Patient Readmission | 1 | 2020 | 3249 | 0.260 |
Why?
|
Immunoglobulin M | 5 | 2020 | 1530 | 0.250 |
Why?
|
Propionibacteriaceae | 1 | 2024 | 10 | 0.240 |
Why?
|
Visual Acuity | 2 | 2024 | 2662 | 0.240 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2016 | 369 | 0.240 |
Why?
|
Photophobia | 1 | 2024 | 75 | 0.230 |
Why?
|
Vaccines, Virus-Like Particle | 1 | 2024 | 45 | 0.220 |
Why?
|
Eye Diseases, Hereditary | 1 | 2024 | 122 | 0.220 |
Why?
|
Retinal Cone Photoreceptor Cells | 1 | 2024 | 184 | 0.210 |
Why?
|
Immunoglobulin A | 3 | 2020 | 980 | 0.210 |
Why?
|
Retinal Rod Photoreceptor Cells | 1 | 2024 | 204 | 0.210 |
Why?
|
Viral Load | 7 | 2021 | 3329 | 0.210 |
Why?
|
Coronavirus | 2 | 2021 | 153 | 0.200 |
Why?
|
Aluminum Hydroxide | 1 | 2022 | 54 | 0.200 |
Why?
|
HIV Infections | 7 | 2023 | 17328 | 0.200 |
Why?
|
Myopia | 1 | 2024 | 251 | 0.200 |
Why?
|
Immunoglobulin G | 7 | 2020 | 4549 | 0.190 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2024 | 343 | 0.190 |
Why?
|
Anti-HIV Agents | 1 | 2017 | 4518 | 0.190 |
Why?
|
Vimentin | 1 | 2022 | 255 | 0.190 |
Why?
|
Virus Internalization | 2 | 2022 | 496 | 0.180 |
Why?
|
Hospital Charges | 1 | 2023 | 351 | 0.180 |
Why?
|
Receptors, IgG | 2 | 2021 | 559 | 0.180 |
Why?
|
HIV-1 | 4 | 2023 | 6859 | 0.180 |
Why?
|
Genetic Diseases, X-Linked | 1 | 2024 | 386 | 0.180 |
Why?
|
Nucleocapsid Proteins | 1 | 2020 | 76 | 0.180 |
Why?
|
Immunity, Maternally-Acquired | 1 | 2020 | 111 | 0.180 |
Why?
|
B-Lymphocytes | 3 | 2022 | 4748 | 0.170 |
Why?
|
Immunoassay | 2 | 2020 | 746 | 0.170 |
Why?
|
Extracellular Space | 1 | 2022 | 563 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 196 | 0.170 |
Why?
|
Eccrine Glands | 1 | 2020 | 52 | 0.170 |
Why?
|
Macaca mulatta | 3 | 2021 | 2322 | 0.170 |
Why?
|
Antibodies | 3 | 2022 | 2421 | 0.170 |
Why?
|
Calcium-Binding Proteins | 1 | 2024 | 1069 | 0.170 |
Why?
|
Humans | 46 | 2024 | 760437 | 0.170 |
Why?
|
Heparitin Sulfate | 1 | 2020 | 223 | 0.170 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2020 | 3800 | 0.160 |
Why?
|
Skull Neoplasms | 1 | 2020 | 173 | 0.160 |
Why?
|
Enterocytes | 1 | 2020 | 220 | 0.160 |
Why?
|
Mice, Inbred BALB C | 3 | 2022 | 6206 | 0.160 |
Why?
|
Aneurysm, Ruptured | 1 | 2023 | 459 | 0.160 |
Why?
|
Length of Stay | 2 | 2023 | 6413 | 0.150 |
Why?
|
Sweat Gland Neoplasms | 1 | 2020 | 116 | 0.150 |
Why?
|
Protein Engineering | 1 | 2021 | 547 | 0.150 |
Why?
|
Goblet Cells | 1 | 2020 | 298 | 0.140 |
Why?
|
Nasal Mucosa | 1 | 2020 | 415 | 0.140 |
Why?
|
Lost to Follow-Up | 1 | 2017 | 123 | 0.140 |
Why?
|
Pedigree | 1 | 2024 | 4586 | 0.140 |
Why?
|
Adenoviridae | 1 | 2020 | 1084 | 0.130 |
Why?
|
Malawi | 1 | 2017 | 304 | 0.130 |
Why?
|
Pandemics | 9 | 2022 | 8623 | 0.130 |
Why?
|
Interferon Type I | 1 | 2020 | 562 | 0.130 |
Why?
|
Receptors, HIV | 1 | 2016 | 159 | 0.130 |
Why?
|
Mentors | 1 | 2021 | 660 | 0.130 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4369 | 0.130 |
Why?
|
Genitalia, Male | 1 | 2015 | 87 | 0.130 |
Why?
|
Pituitary Neoplasms | 1 | 2024 | 1324 | 0.120 |
Why?
|
Male | 24 | 2024 | 360035 | 0.120 |
Why?
|
Directive Counseling | 1 | 2016 | 170 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.120 |
Why?
|
Viral Vaccines | 1 | 2020 | 596 | 0.120 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 973 | 0.120 |
Why?
|
Vaccines, Synthetic | 3 | 2022 | 619 | 0.120 |
Why?
|
Recombinant Proteins | 2 | 2021 | 6525 | 0.120 |
Why?
|
General Surgery | 2 | 2024 | 1687 | 0.120 |
Why?
|
Schools, Medical | 1 | 2021 | 878 | 0.120 |
Why?
|
Retrospective Studies | 7 | 2024 | 80430 | 0.120 |
Why?
|
Influenza, Human | 2 | 2022 | 1517 | 0.110 |
Why?
|
Fetal Blood | 1 | 2020 | 1346 | 0.110 |
Why?
|
Acute Disease | 1 | 2024 | 7230 | 0.110 |
Why?
|
Spinal Neoplasms | 1 | 2020 | 715 | 0.110 |
Why?
|
Adenoma | 1 | 2024 | 2157 | 0.110 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 5491 | 0.110 |
Why?
|
Mice | 8 | 2024 | 81402 | 0.110 |
Why?
|
Plasma | 1 | 2016 | 585 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1212 | 0.100 |
Why?
|
Withholding Treatment | 1 | 2016 | 617 | 0.100 |
Why?
|
HIV Seropositivity | 1 | 2017 | 960 | 0.100 |
Why?
|
Leadership | 1 | 2021 | 1379 | 0.100 |
Why?
|
Placenta | 1 | 2020 | 1704 | 0.100 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2907 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2020 | 1248 | 0.090 |
Why?
|
Animals | 11 | 2024 | 168253 | 0.090 |
Why?
|
Female | 21 | 2024 | 391875 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 786 | 0.090 |
Why?
|
Prenatal Care | 1 | 2017 | 1134 | 0.080 |
Why?
|
Odds Ratio | 1 | 2021 | 9639 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2022 | 3541 | 0.080 |
Why?
|
Breast Feeding | 1 | 2017 | 1357 | 0.080 |
Why?
|
Cross Reactions | 2 | 2020 | 818 | 0.080 |
Why?
|
Middle Aged | 12 | 2024 | 220382 | 0.080 |
Why?
|
Carcinoma | 1 | 2020 | 2328 | 0.080 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39078 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2016 | 3631 | 0.070 |
Why?
|
Medicaid | 1 | 2020 | 2810 | 0.070 |
Why?
|
Phylogeny | 3 | 2022 | 2806 | 0.070 |
Why?
|
Adult | 10 | 2024 | 220781 | 0.070 |
Why?
|
Sexual Behavior | 1 | 2016 | 2178 | 0.070 |
Why?
|
Antigens | 2 | 2022 | 1446 | 0.070 |
Why?
|
Databases, Factual | 1 | 2021 | 7948 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7424 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2891 | 0.060 |
Why?
|
Serine Endopeptidases | 2 | 2020 | 1021 | 0.060 |
Why?
|
Age Factors | 1 | 2021 | 18379 | 0.060 |
Why?
|
Antibodies, Blocking | 1 | 2024 | 243 | 0.050 |
Why?
|
Incidence | 1 | 2021 | 21322 | 0.050 |
Why?
|
Binding Sites | 2 | 2022 | 6042 | 0.050 |
Why?
|
Influenza B virus | 1 | 2022 | 52 | 0.050 |
Why?
|
Aged | 8 | 2023 | 168840 | 0.050 |
Why?
|
Hemagglutinins | 1 | 2022 | 113 | 0.050 |
Why?
|
Antigenic Variation | 1 | 2022 | 118 | 0.050 |
Why?
|
Cohort Studies | 5 | 2023 | 41366 | 0.050 |
Why?
|
Middle Cerebral Artery | 1 | 2023 | 275 | 0.050 |
Why?
|
Retreatment | 1 | 2024 | 598 | 0.050 |
Why?
|
HEK293 Cells | 2 | 2022 | 4277 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2024 | 15627 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5866 | 0.050 |
Why?
|
Phosphoproteins | 2 | 2020 | 2444 | 0.050 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2022 | 158 | 0.050 |
Why?
|
Carotid Artery, Internal | 1 | 2023 | 440 | 0.050 |
Why?
|
Infant, Newborn | 2 | 2020 | 26280 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14661 | 0.050 |
Why?
|
Haplorhini | 1 | 2021 | 529 | 0.040 |
Why?
|
Mesocricetus | 1 | 2020 | 252 | 0.040 |
Why?
|
Mass Screening | 1 | 2016 | 5424 | 0.040 |
Why?
|
Macrophages | 1 | 2015 | 5764 | 0.040 |
Why?
|
HL-60 Cells | 1 | 2020 | 363 | 0.040 |
Why?
|
Peptide Library | 1 | 2021 | 347 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 191 | 0.040 |
Why?
|
Carcinoma, Ductal | 1 | 2020 | 97 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29551 | 0.040 |
Why?
|
Pregnancy | 2 | 2020 | 29831 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2021 | 901 | 0.040 |
Why?
|
Mutation | 2 | 2021 | 30025 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 397 | 0.040 |
Why?
|
Child | 3 | 2023 | 80086 | 0.040 |
Why?
|
Critical Pathways | 1 | 2023 | 474 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2021 | 754 | 0.040 |
Why?
|
Protein Binding | 2 | 2022 | 9340 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5421 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1703 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2020 | 1060 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2020 | 9003 | 0.040 |
Why?
|
Vaccination | 2 | 2021 | 3375 | 0.040 |
Why?
|
Abdominal Wall | 1 | 2020 | 166 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15820 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2022 | 1340 | 0.040 |
Why?
|
Career Choice | 1 | 2024 | 755 | 0.040 |
Why?
|
Transgenes | 1 | 2021 | 1009 | 0.040 |
Why?
|
Lung | 3 | 2021 | 9973 | 0.040 |
Why?
|
Massachusetts | 2 | 2020 | 8826 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2021 | 987 | 0.040 |
Why?
|
Molecular Dynamics Simulation | 1 | 2020 | 436 | 0.040 |
Why?
|
Influenza A virus | 1 | 2020 | 457 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2020 | 496 | 0.040 |
Why?
|
Scalp | 1 | 2020 | 389 | 0.040 |
Why?
|
Mammals | 1 | 2022 | 1132 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2020 | 13445 | 0.030 |
Why?
|
Cricetinae | 1 | 2020 | 2427 | 0.030 |
Why?
|
Receptors, Virus | 1 | 2020 | 640 | 0.030 |
Why?
|
Virus Attachment | 1 | 2016 | 55 | 0.030 |
Why?
|
United States | 2 | 2024 | 72202 | 0.030 |
Why?
|
Postoperative Care | 1 | 2023 | 1471 | 0.030 |
Why?
|
Dependovirus | 1 | 2021 | 715 | 0.030 |
Why?
|
Cell Line | 2 | 2020 | 15598 | 0.030 |
Why?
|
Adolescent | 2 | 2021 | 88196 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7377 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1337 | 0.030 |
Why?
|
Young Adult | 2 | 2024 | 59068 | 0.030 |
Why?
|
Infant | 1 | 2017 | 36183 | 0.030 |
Why?
|
Education, Medical, Undergraduate | 1 | 2024 | 1066 | 0.030 |
Why?
|
Molecular Typing | 1 | 2015 | 116 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 934 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2021 | 1359 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10188 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2023 | 1859 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1559 | 0.030 |
Why?
|
Risk Factors | 1 | 2021 | 74055 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2296 | 0.030 |
Why?
|
Receptors, CCR5 | 1 | 2016 | 486 | 0.030 |
Why?
|
Africa South of the Sahara | 1 | 2016 | 743 | 0.030 |
Why?
|
Virus Replication | 1 | 2021 | 2435 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3571 | 0.030 |
Why?
|
Heparin | 1 | 2020 | 1633 | 0.030 |
Why?
|
Semen | 1 | 2015 | 346 | 0.030 |
Why?
|
RNA, Viral | 1 | 2020 | 2846 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2016 | 2749 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2020 | 3587 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2016 | 727 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2016 | 2004 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4116 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18216 | 0.020 |
Why?
|
Regression Analysis | 1 | 2020 | 6340 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2020 | 58859 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2020 | 3392 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 2021 | 2687 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 3066 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7208 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2022 | 4430 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5236 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2020 | 4355 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 2020 | 1912 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2413 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10075 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12054 | 0.020 |
Why?
|
Tuberculosis | 1 | 2020 | 2012 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4649 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10494 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 64591 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9267 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4735 | 0.020 |
Why?
|
Kidney | 1 | 2020 | 7046 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2020 | 18955 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26063 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 22121 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 22097 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7582 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3190 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20078 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 12976 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14565 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10180 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 39947 | 0.010 |
Why?
|
Prospective Studies | 1 | 2020 | 54339 | 0.010 |
Why?
|